Free Trial
NASDAQ:BTTX

Better Therapeutics Q1 2023 Earnings Results & Report

Better Therapeutics logo
$0.0001 0.00 (0.00%)
As of 11/3/2026 09:46 AM Eastern

Better Therapeutics reported Q1 2023 earnings on May 11, 2023. The company reported EPS of -$0.39.

Earnings Announcement Details

Quarter
Q1 2023
Report Date

Better Therapeutics EPS Results

Actual EPS
-$0.39
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 6 quarters

Better Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Better Therapeutics' next earnings date is estimated for Thursday, November 12, 2026, based on past reporting schedules.

Conference Call Resources

Better Therapeutics Q1 2023 Earnings FAQ

Better Therapeutics (NASDAQ:BTTX) reported earnings of -$0.39 per share for Q1 2023. The report was announced on Thursday, May 11, 2023.

Better Therapeutics' next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Better Therapeutics on the company's earnings history page.

Better Therapeutics Earnings Headlines

BTTX Better Therapeutics, Inc. - Seeking Alpha
$250,000/Month- How You Can Learn from President Trump
President Trump has reportedly collected up to $250,000 a month from a single fund. Now investors can get access to the same fund for less than $20.tc pixel
Janux Therapeutics Inc (JANX) Receives a Buy from BTIG
See More Better Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Better Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Better Therapeutics and other key companies, straight to your email.

About Better Therapeutics

Better Therapeutics (NASDAQ:BTTX) was a digital therapeutics company focused on developing prescription software designed to address chronic metabolic and cardiometabolic conditions. Its approach combined behavioral therapy, personalized digital coaching and clinical content delivered through software intended for use alongside standard medical care.

The company’s lead product, AspyreRx, formerly known as BT-001, was authorized by the U.S. Food and Drug Administration in 2023 as a prescription digital therapeutic for adults with type 2 diabetes. The software was designed to support behavior change and help patients manage their condition in conjunction with traditional treatment.

Better Therapeutics was based in the United States and primarily targeted the U.S. healthcare market. Following the FDA authorization of AspyreRx, the company announced a strategic review and subsequently reported a wind-down of operations. Information about its current commercial activities and leadership is limited.

View Better Therapeutics Profile